U.S. Electrical Stock News

KBR (NYSE:KBR) has named its planned independent Mission Technology Solutions spin-off "Trinzic." The company also announced executive designations for Trinzic as part of the separation process. This move marks a further step toward formally separating the Mission Technology Solutions business from KBR. KBR operates across government services and technology-focused engineering, with Mission Technology Solutions playing a central role in its defense and intelligence-facing work. The formal...

Brookdale Senior Living (BKD) has drawn fresh attention after its stock closed at $14.62, with recent returns mixed over the past week, month, and past 3 months, and a sharp gain over the past year. See our latest analysis for Brookdale Senior Living. Despite a recent 30 day share price return that is down 9.14%, Brookdale Senior Living still has strong momentum when viewed over a longer horizon, with a 1 year total shareholder return of 88.65% and a 3 year total shareholder return of very...

SELLAS Life Sciences Group (SLS) is back in focus as investors watch for the final analysis of its Phase 3 REGAL trial in acute myeloid leukemia, with the pivotal readout reportedly close. See our latest analysis for SELLAS Life Sciences Group. At a share price of $10.29, SELLAS Life Sciences Group has seen a very large 1 year total shareholder return. The 90 day share price return of 108.72% contrasts with a 30 day share price decline of 30.28%, suggesting momentum has cooled as investors...

In recent months, CAVA Group reported that it has been expanding its restaurant base rapidly, averaging 18.7% annual new-unit growth over the past two years, while also delivering 9.8% year-on-year same-store sales growth that points to rising demand at existing locations. This combination of fast footprint expansion and strong same-restaurant performance sets CAVA apart from much slower-growing peers in the broader restaurant sector, suggesting its Mediterranean concept is resonating across...

Rithm Capital (NYSE:RITM) is weighing a potential shift from its current real estate investment trust structure to a traditional C corporation, according to recent management commentary. The company is also working to expand its third party asset management platform and grow fee based revenue streams. Rithm Capital enters this decision point with shares recently trading around $9.87. The stock is up 9.9% over the past week and 5.1% over the past month, while returns year to date and over...

Hercules Capital stock is coming off a solid 5 year return, yet current checks suggest the market price may still sit below what its fundamentals imply. At the last close of US$15.94, both the intrinsic value estimate from the Excess Returns model and the earnings multiple view point to a market that may be underpricing the company. Hercules Capital has returned 60.3% over the past 5 years, which puts recent short term weakness into a longer term context of gains. Future lending growth and...

ImmunityBio recently reported that the Emirates Drug Establishment granted Marketing Authorization in the UAE for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, expanding the drug’s regulatory reach to 34 countries with its broadest label yet. This is the first worldwide approval to cover the full spectrum of BCG-unresponsive bladder disease, including both carcinoma in situ and papillary-only tumors, while also adding a...

Lumen Technologies (LUMN) is back in focus as investors look ahead to its second quarter 2026 earnings report on August 4, with attention on its multiyear transformation and recent connectivity and security product moves. See our latest analysis for Lumen Technologies. Lumen Technologies’ recent 1-day share price return of 5.13% and 7-day share price return of 0.46% sit against a 30-day share price decline of 14.58% and a 90-day share price decline of 29.61%, while the 1-year total...

Exponent, Inc. has reported past second-quarter 2026 results showing sales of US$148.86 million and revenue of US$171.61 million, with net income rising to US$29.4 million and earnings per share reaching US$0.60, alongside an expanded buyback program totaling US$836.7 million since inception. Alongside stronger earnings driven in part by AI-related consulting demand, Exponent’s increased buybacks and ongoing dividends highlight management’s emphasis on returning capital while supporting its...

Coherent Corp. is set to report its fourth-quarter fiscal 2026 results on August 12, with analysts highlighting its positive Earnings ESP and history of outperforming consensus estimates. At the same time, weaker guidance from peer Corning has cast a cloud over the broader optical and AI data-center supply chain that Coherent helps serve. Next, we’ll examine how anticipation of Coherent’s earnings amid mixed AI optics sentiment could influence its existing investment narrative. Explore 26...

Yum! Brands (YUM) has released its second quarter 2026 earnings, reporting higher sales, revenue, and net income compared with a year earlier. The stock’s movement now reflects how investors interpret these results. See our latest analysis for Yum! Brands. The latest earnings release appears to be the key driver of Yum! Brands’ recent momentum, with a 1-day share price return of 3.34% and a 7-day share price return of 6.53% lifting the stock to US$157. Over a longer stretch, the year to date...

TeraWulf stock has delivered a very large 3 year gain, yet its current valuation checks do not flag it as a clear bargain. After a sharp run and recent pullback, investors are left weighing strong past returns against a weak overall value score. Over the past 3 years, TeraWulf has returned about 5.8x, which puts extra focus on whether today’s price still leaves much room for error. Recent attention around AI data center financing and sector deals may support growth expectations for TeraWulf,...

Heavy spending on AI by Big Tech is creating a clear split in market opinion. Investors are rewarding companies like Microsoft and Amazon that can point to real AI revenue, while punishing those with vague AI ambitions and weak free cash flow such as Alphabet and Meta. At the same time, consumer appetite for new tech and AI features from companies like Apple and Google remains strong. This article looks at 3 Consumer Technology Innovators that are exposed to this AI news cycle and may offer...

In late July 2026, DXC Technology issued earnings guidance pointing to an organic revenue decline for both the second quarter and full fiscal 2027, while also reshaping its leadership team and advancing an AI-focused transformation that includes a new President role and expanded AI innovation remit. Alongside this, DXC deepened its AI ambitions through new senior appointments and a partnership and investment with voice AI company ElevenLabs, aiming to embed advanced voice capabilities across...

Lantheus Holdings (LNTH) has been drawing attention after its shares last closed at US$101. The stock is higher compared with this time last year, although it has moved lower over the past month. See our latest analysis for Lantheus Holdings. For Lantheus Holdings, the 1 day share price return of 1% comes after a 30 day share price return that is down 9%, while the year to date share price return of 50.14% and 1 year total shareholder return of 41.87% point to momentum that has largely been...

Cybersecurity tests that allowed Anthropic’s AI models to breach external firms, along with comparable issues at OpenAI, are a sharp reminder that AI risk is not just technical. It is legal, compliance and reputational. As regulators respond with tighter oversight and higher expectations, spending on legal and compliance services could shift in meaningful ways. For investors, that can mean new potential opportunity or fresh risk depending on how companies sit within this regulatory trend...

Eagle Materials stock slipped about 2.1% today, yet the earnings story is more nuanced than that headline move suggests. Coming into the print, shares had already eased over the past month, so expectations were not stretched. Against that backdrop, the company posted record Q1 fiscal 2027 revenue of US$651 million and basic earnings per share of US$3.30, while still absorbing higher freight costs and a US$6 million hit from downtime at its Mountain cement facility. The market is reacting to...

Carpenter Technology (NYSE:CRS) announced the sudden death of its Chief Executive Officer and President. The Board moved immediately to appoint former long-term CEO Tony Thene as the new Chief Executive Officer. This leadership change was presented as an urgent succession decision aimed at maintaining business continuity. Carpenter Technology operates as a specialty alloys and engineered materials producer, serving aerospace, defense, medical, and industrial end markets. Leadership...

Universal Display (OLED) has drawn investor attention after reporting Q2 2026 earnings that showed lower revenue and net income year on year, while reiterating full year guidance and maintaining its cash dividend. See our latest analysis for Universal Display. The mixed Q2 report appears to sit against a backdrop of weaker recent trading for Universal Display, with the share price at US$80.36, the year-to-date share price return down 34.05%, and the 1-year total shareholder return down...

Morgan Stanley Investment Management recently launched two new Ethereum (MSSE) and Solana (MSOL) exchange-traded products on NYSE Arca that pass staking rewards directly to investors, while the firm also issued US$50.00 million of 4.500% senior unsecured notes due September 28, 2027, and expanded its leadership by hiring Emma Taylor to co-lead global internet banking. This move positions Morgan Stanley among the first major U.S. banks to package yield-bearing crypto exposure into regulated,...

Amgen recently announced that its Board of Directors declared a US$2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026 to shareholders of record as of August 21, 2026. Separately, the European Medicines Agency’s CHMP issued a positive opinion on expanding Repatha’s use to high‑risk adults without prior heart attack or stroke, potentially broadening its clinical role in cardiovascular prevention. We’ll now explore how the CHMP’s positive opinion on expanding...

In late July 2026, Pfizer reported positive Phase 3 results for its oral JAK3/TEC inhibitor LITFULO in nonsegmental vitiligo and secured European Commission approval for its 2026–2027 XFG‑adapted COVID-19 vaccine for individuals six months and older. Together, these milestones highlight Pfizer’s push to build a broader immunology and dermatology franchise while maintaining a recurring role in seasonal COVID-19 vaccination campaigns. With this backdrop, we’ll now examine how LITFULO’s Phase 3...

Arista Networks stock has delivered a very strong multi year return, yet the latest valuation checks suggest the shares no longer stand out as a clear bargain. The intrinsic value estimate from a Discounted Cash Flow (DCF) model sits close to the current price, while market multiples lean rich. Arista Networks has returned about 6x over the past five years, which sets a high bar for any further upside to be justified by fundamentals. The launch of Arista's AI driven Zero Trust Branch...

Relay Therapeutics, a clinical-stage precision medicine company, recently announced it will report its second quarter 2026 results and corporate highlights on 6 August 2026, with investors watching closely for updates on its lead asset zovegalisib and other pipeline programs. Analysts have turned more optimistic ahead of this report, pointing to the potential for an earnings beat alongside progress in the company’s oncology and genetic disease trials as key areas of focus. With attention...